Targeted Oncology Staff

The analysis builds on results from the phase 3 KEYNOTE-689 trial of perioperative pembrolizumab in HNSCC.

The complete response letter did not cite any clinical issues regarding the NDA for 177Lu-edotreotide for GEP-NETs.

During a live event, Sikander Ailawadhi, MD, and participants discussed how the route of CD38-antibody delivery, including a newly approved on-body injector, is shaping frontline regimen selection for transplant-ineligible multiple myeloma.

The FDA's Molecular and Clinical Genetics Panel will meet Sept. 23, 2026, to evaluate GRAIL's premarket approval application for the Galleri MCED test.

A multimodal deep learning model trained in the NSABP B-42 trial and validated in TAILORx predicted late distant recurrence risk in HR-positive breast cancer.

Neoadjuvant inetetamab plus pyrotinib and chemotherapy achieved a 60.2% total pathologic complete response rate in the phase 2 neoPICD trial.

Explore how REMS removal streamlines CAR T access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.

Experts weigh TiNivo-2 and CONTACT-03, urging caution on PD-1 rechallenge in RCC and guiding tivozanib vs cabozantinib choices.

Jazz moves to drop Zepzelca’s second-line SCLC use after LAGOON misses survival, while first-line maintenance combo remains approved.

During a live event, Millie Das, MD, and participants discussed why the case for adding a CTLA-4 inhibitor in PD-L1–low metastatic NSCLC does not hold uniformly once histology is taken into account.

Neo-CheckRay shows iSBRT plus durvalumab boosts pCR in high-risk ER+/HER2− breast cancer, especially PD-L1–negative “cold” tumors, with higher immune toxicity.

FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved absorption.

ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for tumors positive for ROS1 and HER.

During a live event, Midhun Malla, MD, and participants discussed toxicity considerations with third-line therapy selection for KRAS-mutant mCRC.

NCCN now prefers gedatolisib plus fulvestrant, with or without palbociclib, for PIK3CA wild-type HR+/HER2– metastatic breast cancer after endocrine therapy.

The July 2026 oncology roundup spotlights rapid cancer drug approvals, new dosing options, a melanoma virus therapy vote, and key rejections shaping treatment trends.

Digital app-based therapy helps breast cancer survivors reduce anxiety over 12 months; however, depression gains lagged.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

FDA fast-tracks ISM6331 for hard-to-treat pleural mesothelioma, spotlighting Hippo pathway targeting and early phase 1 results presented at ESMO 2026.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

SimpleScreen CRC has demonstrated a sensitivity of 81.1% for CRC detection.

Responses seen in more than half of treatment-naive patients, including those with low PD-L1 expression, in the TROPION-Lung02 study.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.

FIT-001 updates show darlifarnib plus cabozantinib drives 33% to 50% responses and 13‑month PFS in pretreated patients with cabozantinib-naive ccRCC.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

FDA clears zidesamtinib for previously treated ROS1-positive metastatic NSCLC, showing 44% responses, CNS activity, and manageable safety in ARROS-1 trial.

Explore second-line options after ICI failure in metastatic ccRCC, featuring TiNivo-2 insights and tivozanib’s tolerability and PFS.

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.